Cancer research, 2020, 08-15, Volume: 80, Issue:16
Survival for high-risk neuroblastoma remains poor and treatment for relapsed disease rarely leads to long-term cures. Large sequencing studies of neuroblastoma tumors from diagnosis have not identified common targetable driver mutations other than the 10% of tumors that harbor mutations in the anaplastic lymphoma kinase ( Topics: Aminopyridines; Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Genes, ras; Heterografts; Humans; Indoles; Male; MAP Kinase Signaling System; Mice, Inbred NOD; Mice, SCID; Mitogen-Activated Protein Kinase Kinases; Mutation; Neoplasm Recurrence, Local; Neuroblastoma; Piperidines; Protein Tyrosine Phosphatase, Non-Receptor Type 11; Pyridones; Pyrimidines; Pyrimidinones; Pyrroles; Triazoles; Vemurafenib | 2020 |